SIRNAOMICS-B (02257) announced its financial results for the year ended December 31, 2025. The Group's research and development expenses were $10.311 million, a decrease of 50.43% year-on-year. The annual net loss was $14.605 million, representing a significant reduction of 70.93% compared to the previous year.
According to the announcement, the decrease in the annual loss was primarily attributable to a reduction in the fair value loss on financial assets measured at fair value through profit or loss, lower administrative expenses, and decreased R&D spending. These factors were partially offset by a decrease in the fair value gain on financial liabilities measured at fair value through profit or loss.
Comments